MAIA Biotechnology reports 88% disease control in lung cancer study
The pooled Phase 2 analysis covers 43 evaluable patients, while a randomized Phase 3 survival analysis is planned for 2027.

Disease control reached 88 per cent in an expanded Phase 2 lung-cancer dataset as MAIA Biotechnology, Inc. NYSEAMERICANMAIA reported updated ateganosine results on Tuesday. The pooled analysis counted 38 of 43 evaluable patients with stable disease or better.
The Nov. 17 release describes treatment with ateganosine at 180 milligrams followed by cemiplimab in 21-day cycles. Participants had advanced non-small cell lung cancer that progressed after checkpoint inhibitor therapy and chemotherapy. MAIA expects an interim survival analysis from its separate Phase 3 trial in 2027.
MAIA is a clinical-stage biotechnology company developing targeted cancer therapies, with ateganosine as its lead program.
Shares last closed at US$1.01 on NYSE American at 4:00 p.m. EST on Nov. 16, according to Google Finance's NYSEAMERICANMAIA page. That close preceded Tuesday's announcement and provides no measure of investors' response to the update.
The new disease-control figure uses an Oct. 1 data cutoff and combines Parts A, B and C of THIO-101. Eligibility for the efficacy analysis required at least one tumour scan after treatment began, so the denominator represents evaluable patients rather than total enrollment.
MAIA's July 8 update reported disease control in 19 of 21 evaluable Part C patients. That was a 90.5 per cent rate using a July 6 cutoff.
The July figure covered Part C alone, while Tuesday's result pools all three parts. The releases therefore do not supply matching snapshots from which to calculate a change in Part C's disease-control rate.
"To date, the trial's combined study data have consistently demonstrated stable disease or better at the first tumor assessment following treatment initiation," MAIA chief executive Vlad Vitoc said in Tuesday's release.
THIO-101 is an open-label, dose-finding study whose primary clinical endpoint is overall response rate. Tuesday's release does not update that endpoint or provide a survival result, p value or confidence interval for the disease-control finding.
MAIA again described the treatment's safety profile as acceptable in heavily pretreated patients, as it did in July; the November update supplied no adverse-event counts, severity breakdown or discontinuation rates.
Read more: SELLAS Life Sciences reports Phase 3 leukemia survival benefit
Phase 3 Compares Overall Survival
The randomized THIO-104 study compares ateganosine followed by checkpoint inhibition against investigator-selected chemotherapy, according to MAIA's Sept. 22 trial update. Its primary clinical endpoint is median overall survival, providing a controlled test beyond the earlier disease-control observations.
The September release said the U.S. Food and Drug Administration granted ateganosine Fast Track designation in July 2025. Tuesday's release says further Part C data may support an accelerated approval filing, but reports no FDA agreement that the disease-control result is sufficient for approval.
The listed peer group includes Summit Therapeutics Inc. NASDAQSMMT, whose shares were US$14.15 at 4:00 p.m. EST on Nov. 13, according to Google Finance's NASDAQSMMT page. The different trading date prevents a same-session comparison with MAIA's quoted close.
Read more: Summit Therapeutics reports FDA refusal for lung cancer treatment
The broader State Street SPDR S&P Biotech ETF NYSEARCAXBI was US$145.88 at 8:00 p.m. EST on Nov. 16, according to Google Finance's NYSEARCAXBI page. That sector benchmark also predates MAIA's clinical announcement.
Tuesday's clinical update gives no cash balance or funding-runway estimate. It therefore does not establish whether current resources cover the planned survival analysis.
The next dated efficacy milestone in Tuesday's release is THIO-104's interim survival analysis in 2027. That analysis is intended to assess the treatment against chemotherapy on the pivotal study's survival measure.
Adrian Kessler






